European Medicines Agency confirms positive benefit-risk balance of RotaTeq

View source ↗

Summary

The EMA confirms a positive benefit-risk balance for RotaTeq, supporting its continued use.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rotavirus Gastroenteritis

Drugs mentioned

• RotaTeq (rotavirus vaccine, pentavalent)